ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /化合物

3-(1-Methylpyrrolidin-2-yl)pyridine

HCID 942
ノートを作成反応を作成見積依頼を出す
印刷プレビュー
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
22083-74-5
標準SMILES
CN1CCCC1c1cccnc1
InChIKey
SNICXCGAKADSCV-UHFFFAOYSA-N
分子式
C10H14N2
平均分子量
162.23 g/mol
単同位体質量
162.11569846

概要

3-(1-methylpyrrolidin-2-yl)pyridine is an N-alkylpyrrolidine that consists of N-methylpyrrolidine bearing a pyridin-3-yl substituent at position 2. It is a pyridine alkaloid, a pyrrolidine alkaloid and a N-alkylpyrrolidine.

名称と識別子

優先名称
3-(1-Methylpyrrolidin-2-yl)pyridine
IUPAC
3-(1-methylpyrrolidin-2-yl)pyridine

名称と別名

3-(1-methylpyrrolidin-2-yl)pyridineDL-NicotineDTXSID3048154CHEBI:1380003-[1-Methylpyrrolidin-2-yl]pyridineRefChem:489602(+-)NICOTINEDTXCID9028128623-834-222083-74-5(+/-)-Nicotine(R,S)-Nicotine
名称をさらに表示
rac-Nicotine(RS)-Nicotine(+-)-Nicotine75202-10-7CHEMBL440464S-(-)-Nicotinedestruxolfumeto bac

データベース識別子

CAS
22083-74-5、54-11-5
PubChem CID
942
DTXSID
DTXSID3048154
ChEMBL
CHEMBL440464
ChEBI
CHEBI:138000
EC Number
623-834-2
Nikkaji
J23.948H

物性

構造計算による物性

XLogP
1.2
極性表面積
16.1 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
1
重原子数
12
形式電荷
0
複雑度
147

実験および物理化学的性質

DrugsPharmaceuticals

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (92.7%): Toxic if swallowed [Danger Acute toxicity, oral]

P262, P264, P270, P273, P280, P301+P316, P302+P352, P316, P321, P330, P361+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 41 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 3 (92.7%)

毒性情報

Treatment · 1 件

Other supportive measures include diazepam or barbiturates for seizures, atropine for excessive bronchial secretions or diarrhea, respiratory support for respiratory failure, and vigorous fluid support for hypotension and cardiovascular collapse. (L1712)

Health EffectsNicotine has mood-altering effects that may include relaxation, sharpness, calmness, and alertness. It may act as a stimulant or sedative/pain killer, depending on the dosage. (L327)
Exposure Routes · 1 件

Oral (L327) ; Inhalation (L327) Absorption of nicotine through the buccal mucosa is relatively slow and the high and rapid rise followed by the decline in nicotine arterial plasma concentrations seen with cigarette smoking are not achieved with the inhaler. About 10% of absorbed nicotine is excreted unchanged in urine.

Toxicity Summary · 1 件

Nicotine is a stimulant drug that acts as an agonist at nicotinic acetylcholine receptors. These are ionotropic receptors composed up of five homomeric or heteromeric subunits. In the brain, nicotine binds to nicotinic acetylcholine receptors on dopaminergic neurons in the cortico-limbic pathways. This causes the channel to open and allow conductance of multiple cations including sodium, calcium, and potassium. This leads to depolarization, which activates voltage-gated calcium channels and allows more calcium to enter the axon terminal. Calcium stimulates vesicle trafficking towards the plasma membrane and the release of dopamine into the synapse. Dopamine binding to its receptors is responsible the euphoric and addictive properties of nicotine. Nicotine also binds to nicotinic acetylcholine receptors on the chromaffin cells in the adrenal medulla. Binding opens the ion channel allowing influx of sodium, causing depolarization of the cell, which activates voltage-gated calcium channels. Calcium triggers the release of epinephrine from intracellular vesicles into the bloodstream, which causes vasoconstriction, increased blood pressure, increased heart rate, and increased blood sugar.

化学と産業

薬理情報

Metabolism/Metabolites · 2 件

Nicotine has known human metabolites that include Nicotine N-glucuronide.

As nicotine enters the body, it is distributed quickly through the bloodstream and can cross the blood-brain barrier. On average it takes about seven seconds for the substance to reach the brain when inhaled. The half life of nicotine in the body is around two hours. Nicotine is metabolized in the liver by cytochrome P450 enzymes (mostly CYP2A6, and also by CYP2B6). A major metabolite is cotinine. Other primary metabolites include nicotine N'-oxide, nornicotine, nicotine isomethonium ion, 2-hydroxynicotine and nicotine glucuronide. (L327) Route of Elimination: About 10% of the nicotine absorbed is excreted unchanged in the urine. Half Life: Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours

用途と製造

Uses · 1 件

Nicotine is highly toxic alkaloid found in the nightshade family of plants (Solanaceae). (L327) NICOTROL Inhaler is indicated as an aid to smoking cessation for the relief of nicotine withdrawal symptoms. NICOTROL Inhaler therapy is recommended for use as part of a comprehensive behavioral smoking cessation program. It is used for the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.

関連反応

61 件
反応記録を作成
HRID 11750 の反応式
HRID 11750反応物としてuspto-grants-2006_08
HRID 15380 の反応式
HRID 15380反応物としてuspto-grants-2010_06
HRID 31084 の反応式
HRID 31084反応物としてuspto-grants-2008_09
HRID 44666 の反応式
HRID 44666反応物としてuspto-grants-2013_09
HRID 55545 の反応式
HRID 55545反応物としてuspto-grants-1997_04
HRID 59711 の反応式
HRID 59711生成物としてuspto-grants-2016_09
HRID 175040 の反応式
HRID 175040生成物としてTraining data from https://doi.org/10.1039/C8SC04228D (6/10)
HRID 218056 の反応式
HRID 218056反応物としてuspto-grants-2012_06
1 / 8 ページ

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
その他の操作
ノートを作成反応を作成見積依頼を出す
Signs and SymptomsSymptoms of overdose include nausea, abdominal pain, vomiting, diarrhea, diaphoresis, flushing, dizziness, disturbed hearing and vision, confusion, weakness, palpitations, altered respiration and hypotension.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Toxicity DataLD50: 140 mg/kg (Dermal, Rat) LD50: 25 mg/kg (Subcutaneous, Rat) LD50: 5900 ug/kg (Intraperitoneal, Mouse) LD50: 2.8 mg/kg (Intravenous, Rat) (T80) LD50: 24 mg/kg (Oral, Mouse) (T18)